NCT00772538 - Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I) | Biotech Hunter

Enrollment

459

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2011

Conditions

Asthma

Interventions

DRUG

tiotropium 5mcg/day

Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo

DRUG

placebo

Matching placebo

Trial Locations (73)

Unknown

205.416.01007 Boehringer Ingelheim Investigational Site, Birmingham

205.416.01012 Boehringer Ingelheim Investigational Site, Los Angeles

205.416.01018 Boehringer Ingelheim Investigational Site, Los Angeles

205.416.01016 Boehringer Ingelheim Investigational Site, Riverside

205.416.01008 Boehringer Ingelheim Investigational Site, San Diego

205.416.01004 Boehringer Ingelheim Investigational Site, Walnut Creek

205.416.01010 Boehringer Ingelheim Investigational Site, Stamford

205.416.01023 Boehringer Ingelheim Investigational Site, Tallahassee

205.416.01002 Boehringer Ingelheim Investigational Site, Elk Grove Village

205.416.01003 Boehringer Ingelheim Investigational Site, Lexington

205.416.01014 Boehringer Ingelheim Investigational Site, Wheaton

205.416.01025 Boehringer Ingelheim Investigational Site, North Dartmouth

205.416.01022 Boehringer Ingelheim Investigational Site, Columbia

205.416.01021 Boehringer Ingelheim Investigational Site, Boys Town

205.416.01011 Boehringer Ingelheim Investigational Site, Cherry Hill

205.416.01001 Boehringer Ingelheim Investigational Site, Cincinnati

205.416.01024 Boehringer Ingelheim Investigational Site, Oklahoma City

205.416.01017 Boehringer Ingelheim Investigational Site, Lake Oswego

205.416.01019 Boehringer Ingelheim Investigational Site, El Paso

205.416.01009 Boehringer Ingelheim Investigational Site, Richmond

205.416.61001 Boehringer Ingelheim Investigational Site, Daw Park

205.416.61002 Boehringer Ingelheim Investigational Site, Woodville

205.416.61003 Boehringer Ingelheim Investigational Site, Nedlands

205.416.02001 Boehringer Ingelheim Investigational Site, Toronto

205.416.02002 Boehringer Ingelheim Investigational Site, Montreal

205.416.02003 Boehringer Ingelheim Investigational Site, Montreal

205.416.02004 Boehringer Ingelheim Investigational Site, Québec

205.416.45001 Boehringer Ingelheim Investigational Site, Hvidovre

205.416.45002 Boehringer Ingelheim Investigational Site, Odense C

205.416.49002 Boehringer Ingelheim Investigational Site, Berlin

205.416.49003 Boehringer Ingelheim Investigational Site, Gelnhausen

205.416.49005 Boehringer Ingelheim Investigational Site, Koblenz

205.416.49004 Boehringer Ingelheim Investigational Site, Oschersleben

205.416.39001 Boehringer Ingelheim Investigational Site, Pisa

205.416.39002 Boehringer Ingelheim Investigational Site, Sesto S. Giovanni (MI)

205.416.81007 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo

205.416.81004 Boehringer Ingelheim Investigational Site, Inashiki-gun, Ibaraki

205.416.81006 Boehringer Ingelheim Investigational Site, Kamogawa, Chiba

205.416.81012 Boehringer Ingelheim Investigational Site, Maebashi, Gunma

205.416.81008 Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo

205.416.81009 Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo

205.416.81001 Boehringer Ingelheim Investigational Site, Naka-gun, Ibaraki

205.416.81014 Boehringer Ingelheim Investigational Site, Noda, Chiba

205.416.81015 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

205.416.81016 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

205.416.81002 Boehringer Ingelheim Investigational Site, Sendai, Miyagi

205.416.81010 Boehringer Ingelheim Investigational Site, Shinagawa-ku, Tokyo

205.416.81005 Boehringer Ingelheim Investigational Site, Tsukuba, Ibaraki

205.416.81011 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa

205.416.81003 Boehringer Ingelheim Investigational Site, Yonezawa, Yamagata

205.416.31005 Boehringer Ingelheim Investigational Site, Breda

205.416.31001 Boehringer Ingelheim Investigational Site, Groningen

205.416.31004 Boehringer Ingelheim Investigational Site, Helmond

205.416.31003 Boehringer Ingelheim Investigational Site, Zutphen

205.416.07001 Boehringer Ingelheim Investigational Site, Moscow

205.416.07002 Boehringer Ingelheim Investigational Site, Moscow

205.416.07003 Boehringer Ingelheim Investigational Site, Reutov - Moscow Region

205.416.38101 Boehringer Ingelheim Investigational Site, Belgrade

205.416.38102 Boehringer Ingelheim Investigational Site, Kragujevac

205.416.38103 Boehringer Ingelheim Investigational Site, Zemun

205.416.27001 Boehringer Ingelheim Investigational Site, Cape Town

205.416.27002 Boehringer Ingelheim Investigational Site, Durban

205.416.27003 Boehringer Ingelheim Investigational Site, Durban

205.416.27004 Boehringer Ingelheim Investigational Site, Pretoria

205.416.90001 Boehringer Ingelheim Investigational Site, Istanbul

205.416.90002 Boehringer Ingelheim Investigational Site, Izmir

205.416.38002 Boehringer Ingelheim Investigational Site, Kharkiv

205.416.38001 Boehringer Ingelheim Investigational Site, Kiev

205.416.38003 Boehringer Ingelheim Investigational Site, Vinnytsia

205.416.44003 Boehringer Ingelheim Investigational Site, Brighton

205.416.44002 Boehringer Ingelheim Investigational Site, Leicester

205.416.44004 Boehringer Ingelheim Investigational Site, Nottingham

205.416.44005 Boehringer Ingelheim Investigational Site, Nottingham